The Food and Drug Administration has approved a latest medicine for hepatitis C. Experts are hoping this new drug will reduce the side effects caused by other treatments.
Olysio, the new drug, will work as antiviral drug to treat some classes of grown-up patients with Hepatitis C. These include patients who are suffering from cirrhosis or any other liver-related disease but their liver is functional, patients who are never treated for Hepatitis C virus and patients who have not seen any improvement in their condition even after treatment.
Experts are seeing this approval of Olysio as a positive sign because patients can get rid of “interferon”, a drug used by Hepatitis C patients, which has severe side effects.
Dr. Douglas Dieterich, director of outpatient hepatology at the Icahn School of Medicine at Mount Sinai (New York City), said, “the approval of Olysio is the first step toward once daily interferon-free treatment of hepatitis C.”
The FDA approval came after six clinical trials, which checked Olysio by combining it with peginterferon-alfa and ribavirin.
Peginterferon-alfa and ribavirin are medicines widely used by Hepatitis C patients.
Hepatitis C attacks liver; limiting its function, destroying it completely and eventually resulting in death. US Centers for Disease Control and Prevention stats show that 3.2 million Americans are affected by Hepatitis C.